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A simple technique for routine, reproducible global surveillance of the drug susceptibility status of the
anaerobic protozoa Trichomonas, Entamoeba, and Giardia is described. Data collected using this technique can
be readily compared among different laboratories and with previously reported data. The technique employs
a commercially available sachet and bag system to generate a low-oxygen environment and log2 drug dilutions
in microtiter plates, which can be monitored without aerobic exposure, to assay drug-resistant laboratory lines
and clinically resistant isolates. MICs (after 2 days) of 3.2 and 25 mM indicated metronidazole-sensitive and
highly clinically resistant isolates of T. vaginalis in anaerobic assays, respectively. The aerobic MICs were 25
and >200 mM. MICs (1 day) of 12.5 to 25 mM were found for axenic lines of E. histolytica, and MICs for G.
duodenalis (3 days) ranged from 6.3 mM for metronidazole-sensitive isolates to 50 mM for laboratory metron-
idazole-resistant lines. This technique should encourage more extensive monitoring of drug resistance in these
organisms.
One of the most important issues for future biomedical
research is the development of antimicrobial resistance and the
lack of coordinated multinational surveillance mechanisms
(25). Overuse and abuse, inappropriate treatment regimens,
and over-the-counter sales of cheap and effective drugs in
many parts of the world have already rendered chloroquine,
penicillin, and methicillin ineffective against Plasmodium falci-
parum, Streptococcus pneumoniae, and Staphylococcus aureus,
respectively (17, 44).
Infections by the anaerobic protozoa Trichomonas vaginalis,
Giardia duodenalis, and Entamoeba histolytica are treated with
metronidazole (Flagyl) or one of the related 5-nitroimidazole
family of drugs such as tinidazole (Fasigyn) (1, 21, 31, 40).
Metronidazole is the only drug approved for the treatment of
trichomoniasis in some countries, the only safe treatment for
invasive amoebiasis, and the favored treatment for giardiasis
(40). It is cheap, easy to produce, safe, and effective; as a result,
it is widely prescribed for a host of ailments including the
treatment of infections by anaerobic bacteria including Helico-
bacter pylori (13), for prophylaxis, and postoperatively (39, 40).
It is sold over the counter in many Asian countries, where
optimal courses of treatment are rarely recommended or taken
(43). Albendazole (Zentel) is an alternative for the treatment
of giardiasis, with 62 to 95% reported efficacy compared with
97% for metronidazole (16).
Trichomonal infection of women ranges from an asymptom-
atic carrier state to profound, acute, inflammatory disease (28).
Infections have been linked to sterility problems, low birth
weight, and preterm delivery (30). These in turn are closely
associated with high infant mortality. It is now generally ac-
cepted that T. vaginalis infection predisposes carriers to human
immunodeficiency virus (HIV) and AIDS (8, 9) and cervical
cancer (41). Given the prevalence of T. vaginalis, and conse-
quent attributable risk to HIV transmission, screening for and
treatment of Trichomonas could prove to be the single most
cost-effective step in HIV incidence reduction (4). Giardiasis is
a significant gut pathogen causing acute and chronic diarrhea
and failure to thrive in children (12). In Mexico alone, approx-
imately 10% of the population has had an episode of invasive
amoebiasis and a significant number will succumb to amoebic
abscesses (7).
Drug failures in trichomoniasis treatment appeared soon
after metronidazole was introduced in the 1960s (40; see ref-
erence 24 for references), and there has been an alarming
increase in recent years (32). Resistance has recently been
confirmed among clinical isolates of Giardia via difficult in vivo
assays (22). In a concerted effort to sustain the usefulness of
this very valuable drug, uniform assays for the assessment of its
susceptibility in anaerobic assays need to be established for
current as well as future worldwide comparisons.
In the past, susceptibility assays have been monitored for a
variety of end points and reported as 50% inhibitory concen-
trations (IC50) for Giardia ranging from 0.01 to 1 mg/ml, 50%
inhibitory dose (ID50) values of 0.2 and 1.5 mg/ml for Giardia
(see reference 39 for references), minimum lethal concentra-
tions (MLCs) after 72 h of 50 to 100 mM for susceptible
organisms (36) and 11.6 mM for the HM-1 strain of E. histo-
lytica (6), and on MIC of .15 mg/ml indicating resistance in
anaerobic assays after 48 h (24). The assortment of assays
found in the literature prevents comparison of data among
different laboratories. In some cases the method of assay is not
detailed, often as a result of shortage of journal space, and the
experiment is therefore irreproducible (42).
Traditionally two major choices for susceptibility assays have
been available: tube assays and microtiter plate assays. Micro-
titer plates are problematic due to the variability of the anaer-
obic environment and the need to remove the plates from the
anaerobic or low-oxygen environment to monitor the progress
of the assay. Tube assays are too cumbersome and time-con-
suming, with few if any replicates possible. A variety of meth-
ods have been used to generate a low-oxygen environment,
* Corresponding author. Mailing address: Queensland Institute of
Medical Research, PO Royal Brisbane Hospital, Brisbane, Queens-
land 4029, Australia. Phone: 61 7 3362 0369. Fax: 61 7 3362 0105.
E-mail: jacquiU@qimr.edu.au.
1810
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
including nitrogen flushing of parasites in 96-well plates (2),
oxygen regulation of trichomonads in 24-well plates within
anaerobic jars (24), and tube assays containing an oxygen-
depleting medium (15). The aim of this study is to describe a
simplified new method which may be extensively used for the
determination of chemosensitivity in the anaerobic protozoa.
The new method uses the Anaerocult C minisystem (Merck)
for Trichomonas and Giardia and the Anaerocult A system
(Merck) for Entamoeba. The Anaerocult C mini-system gen-
erates a 9% CO2–6% O2 atmosphere after 24 h (manufactur-
er’s data sheet), while the Anaerocult A system generates 18%
CO2–,0.1% O2 within 150 min when used as recommended in
an anaerobic jar (manufacturer’s data sheet). The microtiter
plates are sealed in special incubation bags provided with the
Anaerocult C minisystem together with the sachet which cre-
ates the low-oxygen environment. The plates can be monitored
while sealed within the bags over several days and are incu-
bated in a nongassed 37°C incubator. Parasites are monitored
for viability, and in our experience drug MICs obtained using
log2 drug dilutions provide clear results.
MATERIALS AND METHODS
For methods to be standardized worldwide, equipment must be kept to a
minimum. The following assays require the use of flat-bottom, sterile, tissue
culture microtiter plates, a multichannel pipettor, an incubator, and an inverted
microscope. The low-oxygen environment is generated using the Anaerocult C
minisystem, which comes with special incubation bags in which to seal the
microtiter plates. The bags can be sealed with an Anaeroclip (Merck) or a plastic
bag sealer. The Anaerocult A system was designed for an anaerobic jar, but we
cut one small square from the large (four by two squares) sachet and use it in the
same way as the Anaerocult C minisystem for Entamoeba assays.
Parasite culture and isolates. All parasites were grown in TYI-S-33 (10),
which was supplemented with bile for Giardia assays (19). The parasites were
subcultured three times a week, except for Entamoeba, which was subcultured
twice a week. Parasites to be used in drug susceptibility assays were grown for 1
day following regular subculturing and were in the log phase of growth. Drug-
resistant lines were grown without drug for this period.
The T. vaginalis isolate BRIS/92/STDL/F1623 (F1623) was obtained from a
male patient with pruritus. The metronidazole-resistant line BRIS/92/STDL/
F1623-M1 (F1623-M1) derived from it (5) is routinely maintained in 400 mM
metronidazole. The patient was treated with one 2-g dose of tinidazole and was
clear on follow-up. BRIS/98/BSHC/11147 was obtained from a female who was
similarly treated and was clear on follow-up. The clinically resistant line BRIS/
92/STDL/B7268 was obtained from a woman who had recurrent infection for 18
months (42).
Axenic E. histolytica isolates were HTH-56:MUTM (MUTM) (33) and the
drug-resistant line derived from it, MUTM-M1 (29), the isolate HM1:IMSS
(HM1) (ATCC 30459), and line HM1-M1, which was induced to be metronida-
zole resistant in the same manner and to the same level as described for
MUTM-M1 (unpublished results). Both MUTM-M1 and HM1-M1 are main-
tained in 10 mM metronidazole.
G. duodenalis isolates BRIS/83/HEPU/106 (referred to as 106) and the met-
ronidazole-resistant line BRIS/83/HEPU/106-2ID10 (106-2ID10) (2, 3) were
used. 106 was originally obtained from a child with chronic gastrointestinal
complaints. 106-2ID10 is maintained in 5 mM metronidazole (3). WB1B and the
metronidazole-resistant line WB-M3, which is currently maintained in 58 mM
metronidazole, are long-established cultures (34). The albendazole-resistant line
WB-M3-Alb (37) is currently maintained in 2 mM albendazole. The line was one
of several in which albendazole resistance was induced, and it was derived from
the metronidazole-resistant line WB-M3 (34).
Drug susceptibility assays. Stock solutions (0.1 M) of drug (17.1 mg/ml for
metronidazole; 26.5 mg/ml for albendazole [Sigma]) in N,N-dimethylformamide
(DMF; high-pressure liquid chromatography grade [Sigma]) or dimethyl sulfox-
ide (Sigma) were prepared and stored at 220°C. The stock solution was diluted
in medium to the required concentration. A useful starting concentration was
200 mM, which yields a maximum concentration in the assay of 100 mM (17.1 mg
of metronidazole per ml and 26.5 mg of albendazole per ml). In aerobic
Trichomonas assays, a maximum concentration of at least 200 mM in the wells is
recommended. A similar dilution of DMF or dimethyl sulfoxide was prepared for
control wells. A 200-ml volume of diluted drug was added to wells 1, 3, 4, 6, etc.,
of row A, and 200 ml of diluted DMF was added to wells 2, 5, etc., of a 96-well
flat-bottom, covered tissue culture plate (Costar). A 100-ml volume of medium
was added to all other wells. Double dilutions down the plate were performed,
and the last 100 ml from each well of row H was discarded. A 100-ml volume of
medium containing parasites of the first strain was added to wells in columns 1,
2, 3, 4, 5, and 6. Parasites of a second strain were added to wells in columns 7,
8, 9, 10, 11, and 12. Final drug concentrations in rows A to H were typically 100,
50, 25, 12.5, 6.3, 3.2, 1.6, and 0.8 mM, respectively (17, 8.5, 4.25, 2.12, 1.06, 0.52,
0.26, and 0.13 mg of metronidazole per ml). For each strain and drug concen-
tration, there were four replicates with drug and two without. If other drugs are
to be compared with metronidazole, the replicates and plate arrangement can be
adjusted. However, it is important to ensure sufficient replicated wells to avoid
edge effects for both control and drug-containing wells (a minimum of three wells
for each concentration of drug for each strain is suggested).
For T. vaginalis cultures 5 3 103 trophozoites per well were required for
anaerobic assays and 105 were required for aerobic assays. G. duodenalis assays
used 4 3 104 trophozoites per well, and E. histolytica assays used 1 3 104 per well.
The plate was placed in the incubation bag supplied with the Anaerocult C
minisachets and made anaerobic as specified by the manufacturer for T. vaginalis
and G. duodenalis. For E. histolytica a single square of the Anaerocult A sachet
(there are eight square sections in each sachet) was used. The environment was
made anaerobic as specified by the manufacturer for Anaerocult C mini. The
incubation bag was sealed with a plastic bag sealer or with Anaeroclips and
placed in a 37°C incubator. Multiple use of Anaeroclips (more than three times)
was not successful. Aerobic assay mixtures were placed directly in a nongassed
incubator. Trophozoite growth was monitored on a daily basis by comparing
control and drug-containing wells in the same row using an inverted microscope
while the plate remained in the incubation bag. Trophozoite numbers were
scored using 11 (dead or significantly fewer [not more than 20% coverage of well
surface] and significantly less active, or in the case of Entamoeba, .90% rounded
up, than the control well), 21 (20 to 50% coverage of the well surface and some
parasite motility), 31 (an almost confluent well, much motility), and 41 (a
confluent well). Motility can be difficult to assess in adhering cell lines of T.
vaginalis, in which case well coverage is scored; Giardia was monitored for
motility and confluence; and Entamoeba was monitored for motility and round-
ing-up, which is an indication of drug susceptibility. Rounding-up refers to the
ball-like Entamoeba trophozoite with no evidence of purposeful movement and
no pseudopodia. T. vaginalis assay results were usually very clearly defined after
48 h for both anaerobic and aerobic assays. The results for 72 h were usually the
same as those for 48 h. E. histolytica results were usually clearly defined after
24 h. G. duodenalis assay results were best reported after 72 h.
MICs are defined as the lowest concentration of drug at which a 11 score was
obtained in the majority of the triplicate (or quadruplicate) wells.
RESULTS
T. vaginalis. (i) Anaerobic assays. After 1 day small numbers
of parasites were scored, but by 2 days the control wells were
at least 31. By 3 days the fast-growing drug-sensitive isolates in
the control wells were overgrown while the drug-resistant lines
were 41. Trophozoites growing in 0.8 mM metronidazole were
either 31 or 41. The MIC of metronidazole for F1623, which
is regarded as a susceptible isolate, was the lowest, at 3.2 mM
(most frequently obtained value, the mode) with a range of 1.6
to 6.25 mM (Table 1). The previously uncharacterized drug-
susceptible isolate 11147 was intermediate between the suscep-
tible isolate and the clinically resistant isolate, for which the
minimum MIC was 25 mM. The MIC for laboratory-induced
metronidazole-resistant line F1623-M1 was .100 mM (mode)
(Table 1). A second worker who carried out assays with T.
vaginalis obtained a MIC mode of 1.6 mM for F1623 (12 at-
tempts, 83% frequency, 1.6 to 3.2 range) and a MIC mode of
50 mM for F1623-M1 (3 attempts, 66% frequency, 50 to 200
range). Differences between the data presented in Table 1 and
the above data may be a result of plate scoring. Nevertheless,
the MICs for F1623 were in the 1.6 to 6.3 mM range, the
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drug-sensitive range, and MICs for F1623-M1 were clearly
within the clinically resistant range.
(ii) Aerobic assays. The results of the aerobic assays con-
firmed the ranking of the metronidazole susceptibility of the
isolates observed in the anaerobic assays. The highly metron-
idazole-resistant line F1623-M1 did not grow under aerobic
conditions (Table 1).
E. histolytica. The assays were more reliable when the
Anaerocult A rather than the Anaerocult C system was used
and were best read after 24 h. There was no apparent differ-
ence in the mode (Table 1) of these assays between the line
HM1-M1 and its parent strain. However, at least one assay of
HM1-M1 indicated increased resistance (Table 1).
MUTM-M1 was consistently at least twofold less susceptible to
metronidazole than was the parent strain, MUTM, in the same
assay (Table 1).
G. duodenalis. The MIC for metronidazole-susceptible lines
was 6.3 mM (mode) in these assays, and that for the resistant
lines was consistently higher (Table 1). Although the concen-
tration of metronidazole in which 106-2ID10 is maintained is
low, the strain can survive higher concentration of drug. The
albendazole-resistant line WB-M3-Alb, which was derived
from the metronidazole-resistant line WB-M3, has apparently
lost its resistance to metronidazole but is less susceptible to
albendazole than its parent strain. The reportedly high in vitro
susceptibility of Giardia isolates to albendazole in comparison
with metronidazole (11) was evident (Table 1).
DISCUSSION
One of the difficult aspects of anaerobic drug susceptibility
assays is standardization of the low-oxygen environment. The
Anaerocult systems allow the environment to be duplicated
from experiment to experiment and from laboratory to labo-
ratory. They allow the use of multiwell plates, thus removing
the tedium and unreliable reproducibility of tube assays. These
systems provide the scientific community, including diagnosti-
cians, with a uniform method of carrying out anaerobic drug
susceptibility assays of the anaerobic protozoa so that data for
clinical isolates can be compared both worldwide and with
future data.
More complex and sophisticated drug susceptibility assays
than those described here, with more precise readouts, have
been reported, but these may be difficult to reproduce in some
laboratories. For example, [3H]thymidine uptake (2) has been
used to estimated ID50s, but the cost and accessibility of ra-
TABLE 1. MIC for T. vaginalis, E. histolytica, and G. duodenalis in drug susceptibility assays
Isolate MIC (mM)a No. of attemptsb Frequencyc (%) Range (mM)d
T. vaginalis
Anaerocult C (2 days)
BRIS/92/STDL/F1623 3.2 9 66 1.6–6.3
BRIS/92/STDL/F1623-M1 .100 4 75 50–.100
BRIS/98/BSHC/11147 6.3 4 75 3.2–6.3
BRIS/92/STDL/B7268 25 4 25 25–.100
Aerobic assay (2 days)
BRIS/92/STDL/F1623 25 4 75 12.5–25
BRIS/92/STDL/F1623-M1 Dead
BRIS/92/BHSC/11147 50 4 75 50–100
BRIS/92/STDL/B7268 .200 4 100 .200
E. histolytica, Anaerocult A (1 day)
HTH-56:MUTM 12.5 4 50 12.5–50
HTH-56:MUTM-M1 25 4 50 25–100
HM1:IMSS 25 3 100 25
HM1:IMSS-M1 25 2 50 25–100
G. duodenalis
Anaerocult C (3 days)
BRIS/83/HEPU/106 6.3 13 69 3.2–12.5
BRIS/83/HEPU/106-2ID10 25 3 100 25
WB-1B 6.3 15 80 6.3–12.5
WB-M3 50 3 100 50
WB-M3-Alb 6.3 3 100 6.3
Albendazole assay
BRIS/83/HEPU/106 3.2e 9 44 0.8–3.2
WB-1B 3.2e 11 63 1.6–3.2
WB-M3-Alb 12.5e 3 66 6.3–12.5
a Most frequently obtained MIC of metronidazole (Giardia only) or albendazole or lowest MIC (for BRIS/92/STDL/B7268 and HM1:IMSS-M1).
b Number of 96-well plate assays. Each plate had at least three identical columns of test drug and at least one drug-free control column.
c Percentage of attempts for which the mode was the MIC.
d Range of MICs obtained.
e Albendazole MICs; all other values are metronidazole MICs.
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dioactive compounds and associated equipment in some parts
of the world are prohibitive. Similarly, Kang et al. (18) and
Gero et al. (14) developed antigiardial and antitrichomonal
activity colorimetric assays which employ synthetic substrates
of purine salvage pathway enzymes and require an enzyme-
linked immunosorbent assay reader. Although Meri et al. (24)
reported the use of the Anaerocult A system to create an
anaerobic environment in jars, the bag system that we used will
provide a more reproducible, low-cost assay. Our assays have
been used successfully to assess clinical isolates in Durban,
South Africa (unpublished data), and are being used in India
to establish E. histolytica assays for clinical isolates growing
xenically. Clearly, the assay using axenic lines will have to be
adapted to xenic cultures, since axenic cultures of E. histolytica
are notoriously difficult to establish.
Future considerations include assay of clinical metronida-
zole-resistant Giardia isolates such as those described by
Leme´e et al. (22) and identification of stable clinical metron-
idazole-resistant Entamoeba strains. These stable drug-resis-
tant isolates, together with clinically resistant T. vaginalis
strains, some of which are well characterized in the literature
(27, 42), can be deposited or identified in the American Type
Culture Collection protist bank as a source of positive control
strains that can be used as standards along with laboratory-
induced drug-resistant strains.
The number of trophozoites used in the assays is adjusted to
provide a useful reading after a specified time. For T. vaginalis,
5 3 103 trophozoites per well gave a reliable reading after 48 h;
for E. histolytica, approximately 1 3 104 in 24 h was successful,
and for G. duodenalis, 4 3 104 was reliable after 72 h. Fewer
trichomonads were required because of their rapid growth in
comparison with Giardia, while the size of the E. histolytica
trophozoite in comparison with either Giardia or Trichomonas
was the reason for its relatively low number. Two- to threefold-
lower numbers of trophozoites did not alter the MIC.
It is important to report the MIC as a molar concentration
to standardize the comparison of efficacy between different
drugs, especially if, for example, metronidazole is being com-
pared with another nitroimidazole with a significantly higher
molecular weight.
The MICs reported for metronidazole-resistant lines in the
three different species used do not necessarily correlate with
the amount of metronidazole in which the so-called resistant
lines grow. This emphasizes the need to rigorously report assay
readouts over an established period. The MIC for E. histolytica
in our assays suggests that the parent strains could survive in
approximately 10 mM metronidazole. This is not the case for
long periods, and continued exposure to fresh supplies of drug,
as indicated in our previous work (29), where the resistant line
MUTM-M1 survived in 10 mM metronidazole but the parent
isolate did not, will result in death of the culture. It is possible,
however, to induce levels of resistance in E. histolytica with
parasites maintained in 40 mM metronidazole (45).
The high level of metronidazole resistance reached by
trichomonads (5, 20) reflects the ability of the parasite to
down-regulate all hydrogenosomal function, thus circumvent-
ing metronidazole activation, and to use alternative metabolic
pathways (5). Aerobic versus anaerobic resistance in Trichomo-
nas isolates is an important consideration since most reports
indicate no apparent anaerobic resistance but significant levels
of aerobic resistance (26, 27). The highly metronidazole-resis-
tant laboratory line, F1623-M1, for which the MIC mode is
.100 mM metronidazole, was unable to grow aerobically, as
documented for other resistant trichomonads (26). An anaer-
obic MIC of 25 mM after 48 h for T. vaginalis isolate B7268
provides a MIC for clinical resistance associated with great
difficulty in patient treatment. MICs of 6.3 mM or less appear
to correlate with 5-nitroimidazole susceptibility.
Leme´e et al. (22) correlated clinical resistance to a standard
antigiardial therapy with ID50s of 125, 175, and 149 mg of
metronidazole per kg assayed in a mouse model. Treatment
efficacy correlated with a range of ID50s from 31 to 81 mg/kg.
Thus, an apparently two- to threefold increase in resistance of
the parasite grown in mice is sufficient to indicate clinical
resistance and treatment failures. A threefold decrease in the
activity of the enzyme pyruvate:ferredoxin oxidoreductase (35)
and a twofold decrease in ferredoxin activity (23) in the met-
ronidazole-resistant laboratory line WB-M3 may therefore be
sufficient for clinical resistance. Similarly, a three- to fivefold
increase in MRP activity renders tumor cells resistant to che-
motherapy (46). The reason for using the mouse model for the
assays (22) is the difficulty in establishing in vitro cultures of G.
duodenalis, with the best success rates reporting around 50% of
samples finally established in culture (38).
The 50 mM MIC for the metronidazole-resistant line WB-
M3, which is maintained in 58 mM metronidazole, reflects the
differences in growth conditions in tubes versus the conditions
in the microtiter plate in the Anaerocult C anaerobic environ-
ment and emphasizes the importance of using consistent and
reproducible assay conditions for drug susceptibility assays.
Conversely, the MIC for 106-2ID10, which is grown in 5 mM
metronidazole, is 25 mM in the assay. We have not previously
reported the decreased metronidazole resistance following
long-term growth in the absence of metronidazole in the line
WB-M3, as was evident in WB-M3-Alb. WB-M3 was selected
from surviving trophozoites exposed to high levels of metroni-
dazole following UV mutagenesis (34) and was one of the most
successful survivors when exposed long-term to albendazole
(37). WB-M3 maintains its resistance characteristics for several
days without the drug but has not been tested for sensitivity
after months or years in the absence of metronidazole, simi-
larly to WB-M3-Alb. The line 106-2ID10, which was induced to
be metronidazole resistant following exposure to low levels of
drug, reverted to sensitivity after 22 weeks without drug the
(3).
This simple assay system provides a realistic common refer-
ence assay and is the first step toward global surveillance of the
development of drug resistance in the anaerobic protozoa. It
can be used in any basic laboratory equipped with an incubator
and sterile culture facilities and allows comparisons of the
more sophisticated methods for their interpretation of aerobic
and anaerobic resistance among different isolates and for their
correlation with earlier techniques.
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